HER-2 exon 20 insertion

Treating HER2 Exon-20 Insertion NSCLC with Trastuzumab Deruxtecan - Case Based Panel... https://t.co/CV50GJ05ho via @YouTube In this video Drs. @IbiayiMD and @NIVokes analyze the Destiny Lung 02 study on T-Dxd treatment for patients with HER2 Exon-20 insertion NSCLC. (@cancerGRACE)

ZENITH-20 @JTOonline a phase II study of Poziotinib for HER2 exon 20 insertions-> ORR 39% Md DOR 5.7 mo Md PFS 5.6 mo. One of those TKI w/ annoying adverse events: rash, diarrhea & oral mucositis/ulcers, which are very hard to manage #LCSM @OncoAlert https://t.co/jCjYWFbB34 (@dipeshuprety4)

Prof. Chee Lee presented EGFR and HER2 exon 20 insertion inhibitors. Very concise review on complicated mutation to understand and treat. #LCSM #TASLC (@HHorinouchi)

Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non–Small-Cell Lung Cancer https://t.co/SjrlfhXtu4 (@rschilsky)

Paper recommendation from ⁦@MdCurioni⁩ during the #LungSummit: EGFR and HER2 exon 20 insertions in solid tumours ⁦@DralexGva⁩ ⁦@VivekSubbiah⁩ ⁦@ChristianRolfo⁩ ⁦@UmbertoMalapel1⁩ ⁦@Alfdoc2⁩ https://t.co/VwarJS0CD7 (@alitimumab)

#ODAC Votes Against Poziotinib for HER2 Exon 20 Insertion–Mutated NSCLC https://t.co/mBxQK5l6MM (@Dr_RaviMadan)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment @NatRevClinOncol @OncoAlert @ChristianRolfo https://t.co/hU89fFaOt4 (@VivekSubbiah)

🎯EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment ⁦@NatRevClinOncol⁩ https://t.co/hU89fFaOt4 (@VivekSubbiah)

.@JoelNealMD, of @StanfordMed, discusses the emergence of targets such as HER2 exon 20 insertions and amplification, MET amplification, and NRG1 fusions. #lcsm https://t.co/fKVdC9CeCs (@OncLive)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment @NatRevClinOncol @Alfdoc2 @DralexGva @Al3ssandroRusso @gbanna74 @UmbertoMalapel1 @ChristianRolfo @OncoAlert https://t.co/hU89fFaOt4 (@VivekSubbiah)

16 c EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment @Alfdoc2 @DralexGva @NatRevClinOncol https://t.co/hU89fFaOt4 (@VivekSubbiah)

⭐️Our paper on “EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment” in @NatRevClinOncol made it to cover & featured prominently👏@Alfdoc2 @DralexGva @UmbertoMalapel1 @ChristianRolfo @Al3ssandroRusso @gbanna74 @OncoAlert https://t.co/hU89fFaOt4 (@VivekSubbiah)

EGFR & HER2 exon 20 insertion mutations occur in approximately 0.35% and 0.34%, of all cancers in the @AACR GENIE database & are considerably more prevalent in urothelial, non-small-cell lung, breast and CNS cancers @ChristianRolfo @Alfdoc2 https://t.co/dLIRsjfgxB (@VivekSubbiah)

🎯💥Our paper makes it to top 10 @NatRevClinOncol 2021 🏅 8th most popular paper 👉 EGFR & HER2 exon 20 insertions in solid tumours 👉 In 2021,antibody amivantamab & EGFR TKI mobocertinib were FDA approved for NSCLC EGFR e 20 @OncoAlert @Alfdoc2 https://t.co/TuMQgWNTcw https://t.co/9KA7DbQr8c (@VivekSubbiah)

🎯EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment @NatRevClinOncol @Alfdoc2 @UmbertoMalapel1 @ChristianRolfo @OncoAlert https://t.co/hU89fFaOt4 (@VivekSubbiah)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment ⁦⁦@NatRevClinOncol⁩ https://t.co/hU89fFaOt4 (@VivekSubbiah)

News: The phase 2 ZENITH20 trial suggests that the tyrosine kinase inhibitor poziotinib has therapeutic potential for people with #NSCLC harboring HER2 exon 20 insertions. Reported by Mark Socinski (of @AdventHealth) @marinagarassino et al in @JCO_ASCO https://t.co/LwjrSJxaoX (@MM_Oncology)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment | Nature Reviews Clinical Oncology https://t.co/hU89fFaOt4 (@VivekSubbiah)

🎯EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment #precisionmedicine @NatRevClinOncol @OncoAlert @DralexGva @Alfdoc2 @ChristianRolfo @gbanna74 @UmbertoMalapel1 @AlessandroRusso https://t.co/hU89fFaOt4 (@VivekSubbiah)

New drugs and combination approaches for patients harbouring EGFR or HER2 exon 20 insertions are under investigation. Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic NSCLC https://t.co/VO8SO1n9rc via @JAMAOnc part of @JAMANetwork (@VivekSubbiah)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment ⁦@NatRevClinOncol⁩ https://t.co/hU89fFaOt4 (@VivekSubbiah)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment @NatRevClinOncol @Alfdoc2 @DralexGva https://t.co/hU89fFaOt4 (@VivekSubbiah)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment @NatRevClinOncol @OncoAlert https://t.co/hU89fFaOt4 (@VivekSubbiah)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment @NatRevClinOncol https://t.co/hU89fETd4u (@VivekSubbiah)

⭐️🚨EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment | Nature Reviews Clinical Oncology ⁦@NatRevClinOncol⁩ https://t.co/hU89fFaOt4 (@VivekSubbiah)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment | Nature Reviews Clinical Oncology https://t.co/hU89fFaOt4 (@VivekSubbiah)

⭐️ Don’t miss this fabulous review 👉🏼EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment #precisionmedicine @NatRevClinOncol @OncoAlert @EGFRResisters @EgfrUk https://t.co/hU89fFaOt4 (@VivekSubbiah)

Now in PubMed: #EGFR and #HER2 exon 20 insertions in solid #tumours: from biology to treatment. @Alfdoc2 @DralexGva @Al3ssandroRusso @ChristianRolfo @gbanna74 @VivekSubbiah @OncoAlert https://t.co/TSaUA66YgT (@UmbertoMalapel1)

🚨⭐️ Weekend picture from our new review on EGFR & HER2 exon 20 insertions in solid tumors @NatRevClinOncol in the context of amivantamab & mobocertinib FDA approvals @DralexGva @Al3ssandroRusso @gbanna74 @UmbertoMalapel1 @ChristianRolfo @Alfdoc2 https://t.co/uCGiGZioq9 (@VivekSubbiah)

A step forward to better understand #EGFR and #HER2 exon 20 insertions and direct novel therapies thanks to collaboration and friendship with @Alfdoc2 @DralexGva @VivekSubbiah @Al3ssandroRusso @UmbertoMalapel1 @ChristianRolfo and support by @NatRevClinOncol #LCSM @fpoirccs https://t.co/x1wC9HiJnV (@gbanna74)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment | Nature Reviews Clinical Oncology https://t.co/hU89fFaOt4 (@VivekSubbiah)

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment ⁦@NatRevClinOncol⁩ ⁦@OncoAlert⁩ https://t.co/hU89fFaOt4 (@VivekSubbiah)

Now online, new Review from @DralexGva @VivekSubbiah @Al3ssandroRusso @gbanna74 @UmbertoMalapel1 @ChristianRolfo and @Alfdoc2 on EGFR and HER2 exon 20 insertions in solid tumours, such a timely topic with the recent approval of mobocertinib https://t.co/P28p494JlN (@NatRevClinOncol)

Great news for @Exon20Group Australian HER2 exon 20 insertion mutation patients about ENHERTU and the DESTINY-Lung02 Phase 2 trial from one of our favorite medical oncologists! Congrats to Dr. Gilles Gallant at @DaiichiSankyoUS and @HornLeora at @AstraZeneca #LCSM #HER2 #exon20 (@Exon20Group)

NDA is for Cohort 2 indication, NSCLC with HER2 Exon 20 insertion mutations, pre-treated. (@Alex76877381)

For me the two most impressive thoracic oncology data relative to the current mediocre standards of care are 1) trastuzumab deruxtecan in HER2 exon20 insertion mNSCLC and 2)ipi/nivo in non-epithelioid mesothelioma. These are aggressive diseases where SOC lacking @IASLC @OncoAlert (@PatelOncology)

Promising pan-tumor news for a tough mutation class: BDTX-189 gets FDA fast track for tumors with EGFR or HER2 exon20 insertions and allosteric HER2 muts. These occur in 1-2% of solid tumors. https://t.co/oZom6WDplB #ASCO20 poster, @ErikaHamilton9 et al: https://t.co/fR3cY3woae (@MasonIsraelPhD)

What's in progress for #NSCLC #Lungcancer patients with driver mutations? #KRAS, #EGFR/#HER2 exon 20 insertions, and #HER2 mutation trials are on-going. Here are the trial list from Dr. @NarjustDumaMD. You can't get in these trials if you aren't tested, FYI. #AskYourOncologist (@KellyMercierPh1)

Promising results for EGFR and HER2 exon 20 insertions in phase 1/2. Currently in Trials ongoing. Excited we are close to open in our site the phase 3 for NSCLC first line in EGFR exon 20 insertions #AACR20 @EGFRResisters @UMmedschool @UMGCCC @OncoAlert @lcsmchat (@ChristianRolfo)